Cereius
Cereius is a pre-clinical biotechnology company developing novel therapeutic approaches to treat solid tumor brain metastasis, headquartered in Durham, North Carolina, and founded in 2017.
- Company typePrivate
- Founded2017
- HeadquartersDurham, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Cereius firmographics
Firmographics- Name
- Cereius
- Website
- https://cereius.io
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 1–10 employees
- Short description
- Cereius is a pre-clinical biotechnology company developing novel therapeutic approaches to treat solid tumor brain metastasis, headquartered in Durham, North Carolina, and founded in 2017.
- Ownership category
- akta.pro rank
Cereius industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Neuro-Oncology (HLAKAFAH)
Keywords
Where Cereius is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Cereius business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Cereius product offering
Product offeringCore offering
Cereius is a pre-clinical stage biotechnology company developing novel therapeutic approaches for the treatment of solid tumour brain metastasis. The company's work is centered on early-stage drug discovery and translational research targeting metastatic disease in the brain. It does not yet have approved or commercially available products.
Differentiator
Problem solved
Functional benefit
Companies that use Cereius
Customer profileIdeal customer profiles1 record
Cereius technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cereius competitors and assessment
Company assessmentDirect peers
- Plus Therapeutics: Clinical-stage company developing targeted radiopharmaceuticals for CNS cancers, including brain metastases and recurrent glioblastoma. Highly comparable modality and indication focus to Cereius.
- Kazia Therapeutics: Oncology-focused developer of paxalisib and other brain-penetrant therapies for glioblastoma and brain metastases. Closely comparable CNS oncology pipeline and stage.
- Medicenna Therapeutics: Clinical-stage immuno-oncology company developing IL-2 and IL-4 Superkines for brain tumors and other solid tumors. Comparable brain-cancer focus and pre-clinical-to-early-clinical stage.
- CNS Pharmaceuticals: Clinical-stage company developing therapies for primary and metastatic brain cancers. Comparable patient population and CNS-oncology positioning.
- Kintara Therapeutics: Late-stage developer of therapeutics for CNS cancers, including glioblastoma and brain metastases. Comparable indication focus at a more advanced clinical stage.
- Northwest Biotherapeutics: Developer of DCVax dendritic-cell immunotherapies, including DCVax-L for brain cancer. Comparable brain-cancer immunotherapy orientation.
Emerging players
- MimiVax: Privately held developer of SurVaxM and other immunotherapies for brain tumors. Comparable brain-cancer immunology approach at a similar private, pre-commercial stage.
- ABM Therapeutics: Clinical-stage oncology company developing small molecules designed to cross the blood-brain barrier for brain tumors and metastases. Comparable CNS-penetrant oncology strategy.
Broad incumbents
- Novocure: Commercial-stage company marketing Tumor Treating Fields (Optune) for glioblastoma and other solid tumors. Comparable CNS-oncology focus but at a much later, commercial stage.
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with growing CNS oncology and brain-metastasis imaging/therapy programs. Comparable modality and indication space at a far larger scale.
Market position
Customer concentration
Cereius social profiles
Digital presenceCereius financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cereius leadership team
Management profileNumber of profiles
Profiles3 records
Cereius funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cereius M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cereius
What does Cereius do?
Cereius is a pre-clinical stage biotechnology company developing novel therapeutic approaches for the treatment of solid tumour brain metastasis. The company's work is centered on early-stage drug discovery and translational research targeting metastatic disease in the brain. It does not yet have approved or commercially available products.
When was Cereius founded?
Cereius was founded in 2017. It employs 1 to 10 people.
Where is Cereius based?
Cereius is headquartered in Durham, United States, in the North America region.
Who are Cereius's main competitors?
Direct peers on record are Plus Therapeutics, Kazia Therapeutics, Medicenna Therapeutics, CNS Pharmaceuticals, Kintara Therapeutics and Northwest Biotherapeutics. Emerging players are MimiVax and ABM Therapeutics. Broad incumbents are Novocure and Telix Pharmaceuticals.
Does Cereius have an API?
No public API is recorded for Cereius.
What industry is Cereius in?
Cereius's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAKAFAH, Neuro-Oncology. Its NAICS code is 541714.